Albion News

The OLIM Charity Conference
If you are a trustee of a charity we would very much like you to join us in central London on June 8th for our first Charity Conference. The conference will explore external influences currently facing charity trustees and executives, including global trends, pressures on donors, changing legal frameworks and investment strategies. The agenda will start with registration at 10:00am and finish with drinks and a buffet lunch closing at around 2:30. If you would like to come along then please email vscott@albion.capital with details of your name, email address, postal address and associated... read more
  memsstar Ltd. and Plasma-Therm LLC, both leading providers of semiconductor processing equipment for specialty markets, announced today that they have entered into a distribution agreement for North America.  The agreement gives Plasma-Therm the exclusive rights to distribute all release products (HF and XeF2) as well as self-assembled monolayer (SAM) products from memsstar, adding to Plasma-Therm’s deep silicon etch (DSETM) and plasma-enhanced chemical vapor deposition (PECVD) portfolio. The two companies can now deliver complete MEMS fabrication solutions to customers in North America... read more
  The magazine aims to give you an overview of Albions' recent developments, investment sector insight from our partners and a performance update with a Q&A on our VCTs. We are also delighted to introduce you to OLIM Investment Managers.  To view the magazine electronically, please click here. read more
  Entity Resolution and Network Analytics start-up plans further product development and international expansion Quantexa Limited (“Quantexa” or the “Company”) today announced that it has closed a $3.3 million investment, led by Albion and HSBC. Quantexa’s rapid growth has underpinned a Series A fundraising within its first year, with the new capital used to further accelerate product development and international expansion. Founded in 2016 by a team of world-class software, data and advanced analytics experts, Quantexa currently uses big data analytics to tackle complex financial crime and... read more
Health Investor Awards 2017
  We are very pleased to announce that, once again, Albion has been shortlisted for HealthInvestor of the Year 2017 (investment size < £10million) read more
  Automotive technology specialists SBD win place on league table of Britain’s fastest-growing SME exporters SBD ranked 64th in Sunday Times Lloyds SME Export Track 100 league table More than 50% annual international sales growth over two years Between 2016 and 2020, car manufacturers are predicted to spend €42 billion on connected car services and autonomous technologies Published this weekend, the 3rd annual Sunday Times Lloyds SME Export Track 100 league table ranked Britain’s small and medium-sized enterprises (SME) with the fastest-growing international sales.  This year’s table includes... read more
Exco InTouch which is backed by Scottish Equity Partners (SEP) and Albion, has been acquired by ERT, the leading provider of high-quality patient data collection solutions for use in clinical drug development. The acquisition comes on the back of impressive growth for Nottingham based Exco InTouch.  The combined organisation will provide the biopharmaceutical industry with the most advanced and comprehensive choice for electronic clinical outcome assessments (eCOA), patient engagement and digital health supporting the entire clinical development to commercialisation spectrum – from early... read more
UCLTF
The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Professor Stephen Neidle’s ‘G-Quadruplex’ Targeting project, which has the potential to treat pancreatic and other cancers. Pancreatic cancer is devastating and almost always refractory to treatment, resulting in rapid and near-invariably fatal disease progression, usually within a few months of diagnosis. This outlook has not changed in over 40 years despite significant advances in the understanding of disease mechanisms, and the... read more
  Albion portfolio company, Proveca, announced that it has raised £4m to fund the commercial launch of Sialanar® and the development and commercialisation of its paediatric product portfolio. Sialanar® is a treatment for chronic pathological drooling in children, launched in the UK by Proveca, to be followed by the rest of Europe. The investment was led by Catapult Ventures, managers of the GM&C Life Sciences Fund, alongside Kreos Capital, a leading European provider of growth debt financing, in a deal advised by Longcross Advisers. The investment comes soon after the EU-wide PUMA (... read more
Convertr
Albion has invested £3 million in Convertr Media to aid global expansion. Convertr is an award winning enterprise technology platform, launched in 2011 by entrepreneurs Emma Bowkett, CEO and Clive Brett, which helps advertisers enhance their digital marketing through real-time efficiencies in customer acquisition and data partnerships.   Bowkett, chief executive of Convertr Media said, “We are delighted to be working with Albion, at such an exciting time.  We are looking forward to the next phase of our company’s development, particularly with Robert’s expertise: he brings immense experience... read more

Pages